Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Antifreeze Proteins Block Growth of Ice Crystals by Binding Irreversibly

By BiotechDaily International staff writers
Posted on 28 Feb 2013
Print article
Antifreeze proteins (AFPs) bind irreversibly to ice crystals and prevent their growth even when no more protein is left in solution.

AFPs create a difference between the melting point and freezing point known as thermal hysteresis. The addition of AFPs at the interface between solid ice and liquid water inhibits the thermodynamically favored growth of the ice crystal, while ice growth is kinetically inhibited by the AFPs covering the water-accessible surfaces of the ice. Thermal hysteresis is easily measured in the lab with an instrument called a nanoliter osmometer.

Many organisms are protected from freezing by AFPs, which bind to ice, modify its morphology, and prevent its further growth. Since the initial discovery of AFPs in fish, they have also been found in insects, plants, bacteria, and fungi. These proteins have a wide range of applications in cryomedicine, cryopreservation, and frost protection for transgenic plants and vegetables. AFPs also serve as a model for understanding biomineralization, the processes by which proteins help form bones, teeth, and shells. Nonetheless, the mechanism of action of different types of antifreeze proteins is incompletely understood. Antifreeze proteins evolved independently many times with diverse structures and properties, even in closely related species. Although AFPs were discovered more than 30 years ago and have been studied extensively since then, it is not clear whether all AFPs block ice growth through a unified mechanism of action or if these diverse proteins have distinct binding properties. As measurements of the antifreeze proteins in contact with ice were elusive, this question had not been answered.

To elucidate some of these issues investigators at the Hebrew University of Jerusalem (Israel) and Ohio University (Athens, USA) prepared a fluorescently labeled version of the yellow mealworm (Tenebrio molitor) AFP. This protein is a hyperactive AFP with potency to arrest ice growth hundreds of times greater than that of fish or plant AFPs. Use of the labeled protein allowed for direct microscopic observation of protein-ice crystal interaction in a custom-designed, temperature-controlled microfluidic device.

Results published in the January 8, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) revealed that the binding of hyperactive Tenebrio molitor AFP to ice crystals was practically irreversible, and that surface-bound AFPs were sufficient to inhibit ice crystal growth even in solutions depleted of AFPs. These findings ruled out theories of AFP activity relying on the presence of unbound protein molecules.

Related Links:
Hebrew University of Jerusalem
Ohio University


Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.